Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Mansfield, Stephen Liu, A. Szczesna, L. Havel, Maciej Kzrakowski, M. Hochmair, F. Huemer, G. Losonczy, M. Johnson, M. Nishio, M. Reck, T. Mok, S. Lam, D. Shames, Juan Liu, F. Kabbinavar, A. Sandler, L. Horn (2019)
Abstract CT199: IMpower133: Primary efficacy and safety + CNS-related adverse events in a Ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)Clinical Trials
A. Rossi, M. Maio, P. Chiodini, R. Rudd, H. Okamoto, D. Skarlos, M. Früh, W. Qian, T. Tamura, E. Samantas, T. Shibata, F. Perrone, C. Gallo, C. Gridelli, O. Martelli, S. Lee (2012)
Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 14
M. Reck, Stephen Liu, A. Mansfield, T. Mok, A. Scherpereel, N. Reinmuth, M. Garassino, J. Carpeno, R. Califano, M. Nishio, F. Orlandi, J. Alexander, T. Leal, Ying Cheng, J. Lee, S. Lam, M. McCleland, Y. Deng, S. Phan, L. Horn (2019)
IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)Annals of Oncology
M. Reck, I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, R. Chacko, M. Sebastian, Haolan Lu, J. Cuillerot, T. Lynch (2013)
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.Annals of oncology : official journal of the European Society for Medical Oncology, 24 1
(1995)
Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18? years
T. Mok, M. Reck, L. Horn, S. Lam, D. Shames, J. Liu, F. Kabbinavar, W. Lin, A. Sandler, S. Liu (2018)
IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC).Annals of oncology : official journal of the European Society for Medical Oncology, 29 Suppl 9
Ting Zhou, Zhonghan Zhang, F. Luo, Yuanyuan Zhao, X. Hou, Ting-ting Liu, Kai Wang, Hongyun Zhao, Y. Huang, Li Zhang (2020)
Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung CancerJAMA Network Open, 3
Department of Medical Oncology,
W. Iams, Jason Porter, L. Horn (2020)
Immunotherapeutic approaches for small-cell lung cancerNature Reviews Clinical Oncology, 17
L. Horn, A. Mansfield, A. Szczesna, L. Havel, M. Krzakowski, M. Hochmair, F. Huemer, G. Losonczy, M. Johnson, M. Nishio, M. Reck, T. Mok, S. Lam, D. Shames, Juan Liu, B. Ding, A. López-Chávez, F. Kabbinavar, W. Lin, A. Sandler, Stephen Liu (2018)
First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung CancerThe New England Journal of Medicine, 379
L. Paz-Ares, M. Dvorkin, Yuanbin Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, M. Hochmair, M. Özgüroğlu, J. Ji, O. Voitko, A. Poltoratskiy, S. Ponce, F. Verderame, L. Havel, I. Bondarenko, A. Każarnowicz, G. Losonczy, N. Conev, J. Armstrong, N. Byrne, N. Shire, Haiyi Jiang, J. Goldman, E. Batagelj, I. Casarini, A. Pastor, S. Sena, J. Zarbá, O. Burghuber, S. Hartl, B. Lamprecht, M. Studnicka, L. Schlittler, Fabricio Oliveira, A. Calabrich, G. Girotto, P. Reis, Carlo Gorini, Peo Marchi, C. Baldotto, C. Sette, M. Zukin, A. Dudov, R. Ilieva, K. Koynov, R. Krasteva, I. Tonev, S. Valev, V. Venkova, M. Bi, Chengshui Chen, Yuan Chen, Zhendong Chen, J. Fang, Jifeng Feng, Zhigang Han, Jie Hu, Yi Hu, Wei Li, Zongan Liang, Zhong Lin, R. Ma, Shenglin Ma, K. Nan, Y. Shu, Kai Wang, Mengzhao Wang, Gang Wu, N. Yang, Zhi-Xiong Yang, He-long Zhang, Wei Zhang, Jun Zhao, Yanqiu Zhao, Caicun Zhou, Jianying Zhou, Xiang-dong Zhou, V. Kolek, L. Koubková, J. Roubec, J. Skřičková, M. Zemanova, C. Chouaid, W. Hilgers, H. Léna, D. Moro-Sibilot, G. Robinet, P. Souquet, J. Alt, H. Bischoff, C. Grohé, E. Laack, S. Lang, J. Panse, C. Schulz, K. Bogos, E. Csánky, Anea Fülöp, Z. Horváth, Judit Kósa, I. Laczó, G. Pajkos, Z. Pápai, Zsolt Székely, V. Sárosi, A. Somfay, É. Ezer, Anás Telekes, J. Bar, M. Gottfried, N. Heching, Alona Kuch, R. Bartolucci, A. Bettini, A. Delmonte, M. Garassino, M. Minelli, F. Roila, S. Atagi, K. Azuma, H. Goto, K. Goto, Yu Hara, H. Hayashi, T. Hida, Kenya Kanazawa, S. Kanda, Y. Kim, S. Kuyama, T. Maeda, M. Morise, Y. Nakahara, M. Nishio, N. Nogami, I. Okamoto, H. Saito, M. Shinoda, S. Umemura, T. Yoshida, N. Claessens, R. Cornelissen, Lizza Heniks, Jeroen Hiltermann, E. Smit, A. Brekel, D. Kowalski, S. Mańdziuk, Robert Mróz, M. Wojtukiewicz, T. Ciuleanu, D. Ganea, A. Ungureanu, A. Luft, V. Moiseenko, D. Sakaeva, A. Smolin, Alexander Vasilyev, L. Vladimirova, Igor Anasina, J. Chovanec, P. Demo, R. Godal, P. Kasan, M. Stresko, M. Urda, E. Cho, Joo‐Hang Kim, Sang-We Kim, Gyeong-Won Lee, Jong-Seok Lee, K. Lee, K. Lee, Yun-Gyoo Lee, M. Molla, M. Gómez, J. Mingorance, D. Casado, M. Brea, M. Tarruella, T. Bueno, A. Mendivil, Luis Rodríguez, S. Aix, M. Campelo, G. Chang, Yen-Hsun Chen, C. Chiu, T. Hsia, Kang-Yun Lee, Chien-Te Li, Chin-Chou Wang, Yu-Feng Wei, Shang‐Yin Wu, A. Alacacıoğlu, I. Çiçin, A. Demirkazık, M. Erman, T. Göksel, H. Adamchuk, O. Kolesnik, A. Kryzhanivska, Y. Ostapenko, S. Shevnia, Y. Shparyk, G. Ursol, N. Voitko, I. Vynnychenko, S. Babu, A. Chiang, W. Chua, S. Dakhil, A. Dowlati, Basir Haque, Rodney Jamil, J. Knoble, Shailena Lakhanpal, Kailhong Mi, P. Nikolinakos, S. Powell, H. Ross, E. Schaefer, J. Schneider, Joseph Spahr, D. Spigel, J. Stilwill, C. Sumey, Michael Williamson (2019)
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialThe Lancet, 394
Stephen Liu, M. Reck, A. Mansfield, T. Mok, A. Scherpereel, N. Reinmuth, M. Garassino, J. Carpeño, R. Califano, M. Nishio, F. Orlandi, J. Alatorre-Alexander, T. Leal, Ying Cheng, Jong-Seok Lee, S. Lam, M. McCleland, Y. Deng, S. Phan, L. Horn (2021)
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)Journal of Clinical Oncology, 39
Lorraine Pelosof, D. Gerber (2010)
Paraneoplastic syndromes: an approach to diagnosis and treatment.Mayo Clinic proceedings, 85 9
Julian Higgins, Sally Green (2010)
Cochrane Handbook for Systematic Reviews of InterventionsInternational Coaching Psychology Review
J. Alt, C. Grohé, J. Panse, N. Reinmuth, H. Bischoff, R. Leistner, C. Schulz, H. Laack (2018)
A Phase 3, randomized study of first-line durvalumab (D)+/- tremelimumab (T)+ platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): CASPIANOnkologie, 41
(2006)
Cochrane Handbook for Systematic Reviews of Interventions Edited by Julian P. T. Higgins &
F. Facchinetti, M. Maio, M. Tiseo (2020)
Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized TrialsCancers, 12
L. Paz-Ares, J. Goldman, M. Garassino, M. Dvorkin, D. Trukhin, G. Statsenko, K. Hotta, J. Ji, M. Hochmair, O. Voitko, L. Havel, A. Poltoratskiy, G. Losonczy, N. Reinmuth, Y. Shrestha, N. Patel, H. Mann, Haiyi Jiang, M. Ozguroglu, Y. Chen (2019)
PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIANAnnals of Oncology
V. Konala, B. Madhira, S. Ashraf, S. Graziano (2020)
Use of Immunotherapy in Extensive-Stage Small Cell Lung CancerOncology, 98
L. Paz-Ares, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, M. Hochmair, M. Ozguroglu, J. Ji, O. Voitko, A. Poltoratskiy, S. Ponce, F. Verderame, L. Havel, I. Bondarenko, A. Każarnowicz, G. Losonczy, N. Conev, J. Armstrong, N. Byrne, N. Shire, Haiyi Jiang, J. Goldman (2019)
PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN StudyJournal of Thoracic Oncology
Aaron Mansfield, A. Każarnowicz, N. Karaseva, Á. Sánchez, R. Boer, Z. Andrić, M. Reck, S. Atagi, J. Lee, M. Garassino, Stephen Liu, Leora Horn, X. Wen, C. Quach, Wei Yu, F. Kabbinavar, S. Lam, S. Morris, R. Califano (2020)
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.Annals of oncology : official journal of the European Society for Medical Oncology, 31 2
T. Owonikoko, H. Kim, R. Govindan, N. Ready, M. Reck, S. Peters, S. Dakhil, Atilio Navarro, J. Rodríguez-Cid, M. Schenker, Jong Lee, V. Gutiérrez, I. Percent, D. Morgensztern, Justin Fairchild, C. Baudelet, Keunchil Park (2019)
Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study.Annals of oncology : official journal of the European Society for Medical Oncology, 30 Suppl 2
M. Früh, D. Ruysscher, S. Popat, L. Crinò, Solange Peters, E. Felip (2013)
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 24 Suppl 6
(2017)
Phase I/III trial of atezolizumab with carboplatin and etoposide in ES-SCLC in firstline setting (IMpower133)
(2022)
1–17
U. Lassen, K. Østerlind, M. Hansen, P. Dombernowsky, B. Bergman, H. Hansen (1995)
Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 5
Stephen Liu, A. Mansfield, A. Szczesna, L. Havel, M. Krzakowski, M. Hochmair, F. Huemer, G. Losonczy, M. Johnson, M. Nishio, M. Reck, T. Mok, S. Lam, D. Shames, Juan Liu, B. Ding, F. Kabbinavar, W. Lin, A. Sandler, L. Horn (2018)
PL02.07 IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLCJournal of Thoracic Oncology
H. Sung, J. Ferlay, R. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray (2021)
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesCA: A Cancer Journal for Clinicians, 71
M. Ozguroglu, J. Goldman, N. Reinmuth, Y. Chen, M. Dvorkin, D. Trukhin, G. Statsenko, K. Hotta, J. Ji, M. Hochmair, O. Voitko, L. Havel, A. Poltoratskiy, G. Losonczy, F. Verderame, M. Thomas, Y. Zheng, A. Lloyd, Haiyi Jiang, L. Paz-Ares (2019)
LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIANAnnals of Oncology, 30
Division of Medical Oncology
R. Califano, A. Każarnowicz, N. Karaseva, Á. Sánchez, Stephen Liu, L. Horn, C. Quach, Wei Yu, F. Kabbinavar, S. Lam, A. Mansfield (2018)
IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)Annals of Oncology
D. Moher, A. Liberati, J. Tetzlaff, D. Altman (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA StatementPLoS Medicine, 6
Hirokazu Matsushita, Hirokazu Matsushita, M. Vesely, D. Koboldt, C. Rickert, R. Uppaluri, V. Magrini, C. Arthur, J. White, Yee Chen, L. Shea, J. Hundal, M. Wendl, Ryan Demeter, T. Wylie, J. Allison, Mark Smyth, Mark Smyth, L. Old, E. Mardis, R. Schreiber (2012)
Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer ImmunoeditingNature, 482
T. Seute, P. Leffers, G. Velde, A. Twijnstra (2004)
Neurologic disorders in 432 consecutive patients with small cell lung carcinomaCancer, 100
Shanshan Zhang, M. Bi (2020)
The efficiency and safety of immune checkpoint inhibitors in the treatment of small cell lung cancer: a meta-analysis.Annals of palliative medicine, 9 6
M. Nishio, J. Ji, K. Hotta, C. Chiu, J. Lee, K. Azuma, S. Kim, S. Wu, M. Dvorkin, D. Trukhin, L. Havel, M. Hochmair, M. Ozguroglu, J. Bar, Y. Chen, J. Goldman, N. Byrne, P. Laud, N. Shire, L. Paz-Ares (2019)
Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from AsiaAnnals of Oncology
Hsiao-Ling Chen, Y. Tu, Hsiu-Mei Chang, Tai-Huang Lee, K. Wu, Yu-Chen Tsai, Mei‐Hsuan Lee, Chih-Jen Yang, J. Hung, I. Chong (2020)
Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell CarcinomaCancers, 12
(2008)
Bronchopulmonary neuroendocrine tumors . Cancer [ Internet ]
T. Landre, K. Chouahnia, G. Guetz, B. Duchemann, J. Assié, C. Chouaïd (2020)
First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysisTherapeutic Advances in Medical Oncology, 12
L. Horn, M. Reck, T. Mok, M. Johnson, D. Waterkamp, S. Lam, Xiongwen Tang, A. Sandler, A. López-Chávez, G. Giaccone, Stephen Liu (2016)
A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133)Annals of Oncology, 27
Y. Kawashima, S. Sugawara, S. Atagi, H. Akamatsu, H. Sakai, I. Okamoto, K. Takayama, H. Hayashi, Y. Nakagawa, T. Kawakami, M. Nishio (2019)
Subgroup Analysis of Japanese Patients in a Phase I/III Study of Atezolizumab in ES-SCLC (IMpower133)Annals of Oncology
B. Gustafsson, M. Kidd, A. Chan, M. Malfertheiner, I. Modlin (2008)
Bronchopulmonary neuroendocrine tumorsCancer, 113
(2016)
Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensivestage small-cell lung cancer
(2018)
IMpower133: Patientreported outcomes (PROs) in a ph1/3 study of firstline (1L) atezolizumab (atezo) ? carboplatin ? etoposide (CP/ET) in extensive-stage SCLC (ESSCLC)
J. Higgins, S. Thompson, J. Deeks, D. Altman (2003)
Measuring inconsistency in meta-analysesBMJ : British Medical Journal, 327
C. Rudin, M. Awad, A. Navarro, M. Gottfried, S. Peters, T. Csőszi, P. Cheema, D. Rodríguez-Abreu, M. Wollner, J. Yang, J. Mazières, F. Orlandi, A. Luft, M. Gumus, T. Kato, G. Kalemkerian, Yi Luo, V. Ebiana, M. Pietanza, H. Kim, Keynote Investigators (2020)
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in firstline treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, openlabel
(2019)
LBA1_PR—Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer
Zhicheng Niu, Shenghu Guo, Jing Cao, Yuehua Zhang, Xiaojin Guo, F. Grossi, Y. Ichiki, You Li, Zhiyu Wang (2021)
Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysisAnnals of Translational Medicine, 9
IntroductionThe addition of immune checkpoint inhibitors (ICIs) to conventional chemotherapy (CT) as first-line treatment improves survival in extensive-stage small-cell lung cancer (ES-SCLC). The aim of this meta-analysis was to determine the relative efficacy of first-line ICIs compared with CT in patients with ES-SCLC.MethodsTwo independent reviewers extracted relevant data according to PRISMA guidelines and assessed the risk of bias using the Cochrane Collaboration's risk-of-bias tool. Meta-analysis was conducted using random-effects models to calculate an average effect size for overall survival (OS), progression-free survival (PFS), and safety outcomes in the overall populations and clinically relevant subgroups.ResultsA literature search of PubMed and Embase was performed. Six randomized controlled clinical trials (IMpower133, CHECKMATE-451, CASPIAN, KEYNOTE-604, and phase II and III ipilimumab plus CT trials) with a total of 3757 patients were included. Compared with CT alone, ICIs plus CT showed a favourable effect on OS (hazard ratio [HR] 0.85; 95% confidence intervals [CI] 0.79–0.96) and PFS (HR 0.78; 95% CI 0.72–0.83) but a non-significant increase in the risk of experiencing any adverse event (relative risk, 1.05; 95% CI 0.99–1.11). The estimated HR for OS favoured ICI combinations in all planned subgroups according to age (< 65 years/≥ 65 years), sex (men/women), and ECOG performance status (0/1). Analysis by specific ICI revealed significant improvements in OS only for atezolizumab + CT (HR 1.36; 95% CI 1.09–1.69) and durvalumab + CT (HR 1.35; 95% CI 1.12–1.62) compared with CT alone.ConclusionCombining anti-programmed cell death ligand 1 antibodies with platinum/etoposide is a superior therapeutic approach compared to CT alone for the first-line treatment of patients with ES-SCLC.Graphic abstract[graphic not available: see fulltext]
Oncology and Therapy – Springer Journals
Published: Jun 1, 2022
Keywords: Anti-PD-1/PD-L1 antibodies; Chemotherapy; Immunotherapy; Meta-analysis; Small cell lung carcinoma
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.